Figure 5. Comparison of Liposomal Amphotericin B and Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS

Figure 5. Comparison of Liposomal Amphotericin B and Conventional Amphotericin B for Induction Therapy of Histoplasmosis in Patients with AIDS

This randomized, double-blinded trial involved 81 patients with AIDS and moderate to severe disseminated histoplasmosis. Patients were randomized in a 2:1 ratio to receive intravenous liposomal amphotericin B (AmBisome) 3 mg/kg/d or conventional amphotericin B 0.7 mg/kg/d, for 2 weeks.  For those patient who had successful induction therapy, then received itraconazole for 10 weeks as consolidation therapy. As shown in the figure, patients who received liposomal amphotericin B had higher clinical efficacy of induction therapy (P = 0.014) and less nephrotoxicity (P = 0.003) when compared with those who received conventional amphotericin B.

Data from: Johnson P, Wheat LJ, Cloud G, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137:105-9.

[Close Window]

From: HIV Web Study <www.hivwebstudy.org>
© 2006-11 University of Washington